Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Marianna Mekhaeil, Kumlesh K. Dev, Melissa J. Conroy
Cancers (2022) Vol. 14, Iss. 3, pp. 687-687
Open Access | Times Cited: 20

Showing 20 citing articles:

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 47
Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities
Xiaoxue Xu, Bowen Sun, Chuansheng Zhao
Neurobiology of Disease (2023) Vol. 187, pp. 106314-106314
Open Access | Times Cited: 28
Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Anna Maggiore, Assunta Maria Casale, Walter Toscanelli, et al.
Cells (2022) Vol. 11, Iss. 8, pp. 1284-1284
Open Access | Times Cited: 19
Adenosine diphosphate-ribosylation greatly affects proteins function: a focus on neurodegenerative diseases
Chaowen Huang, Hong Xiao, Yang Yang, et al.
Frontiers in Aging Neuroscience (2025) Vol. 17
Open Access
DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1
Rakesh Srivastava, Niraj Lodhi
Biomolecules (2022) Vol. 12, Iss. 3, pp. 417-417
Open Access | Times Cited: 13
Mitochondria-Targeted Oligomeric α-Synuclein Induces TOM40 Degradation and Mitochondrial Dysfunction in Parkinson’s Disease and Parkinsonism-Dementia of Guam
Muralidhar L. Hegde, Velmarini Vasquez, Manohar Kodavati, et al.
(2024)
Closed Access | Times Cited: 2
Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson’s disease and parkinsonism-dementia of Guam
Velmarini Vasquez, Manohar Kodavati, Joy Mitra, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 12
Open Access | Times Cited: 2
Tryptophan Metabolism ‘Hub’ Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel Disease
Sonia Bustamante, Yunki Yau, Victoria Boys, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14776-14776
Open Access | Times Cited: 11
Recent developments in the role of DNA damage response and understanding its implications for new therapeutic approaches in Alzheimer's disease
Rajesh Ranganathan, G.V. Sapozhnikov, Ni Wang, et al.
Translational Medicine of Aging (2023) Vol. 7, pp. 52-65
Open Access | Times Cited: 5
Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing
V.S. Makeeva, Nadezhda S. Dyrkheeva, Olga I. Lavrik, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16798-16798
Open Access | Times Cited: 5
The Gut Microbiome and Alzheimer’s Disease: A Growing Relationship
Maroun Bou Zerdan, Elsa Hebbo, Ali Hijazi, et al.
Current Alzheimer Research (2022) Vol. 19, Iss. 12, pp. 808-818
Closed Access | Times Cited: 8
The complex universe of inactive PARP1
Doudou Huang, Ziyi Su, Yanxia Mei, et al.
Trends in Genetics (2024)
Closed Access | Times Cited: 1
Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1
Darya O. Koshkina, Natalya Maluchenko, Anna N. Korovina, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1398-1398
Open Access | Times Cited: 1
Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury
Vanessa Martins, Sidnéia Sousa Santos, Larissa de Oliveira Cavalcanti Peres Rodrigues, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3789-3789
Open Access | Times Cited: 7
Transcriptomic Profiling Unveils Novel Therapeutic Options for Drug-Resistant Temporal Lobe Epilepsy
Patricia Sánchez‐Jiménez, Lola Alonso, Laura Cerrada-Gálvez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches
Souhrid Sarkar, Somi Patranabis
Human Cell (2024) Vol. 37, Iss. 5, pp. 1355-1377
Closed Access
Multiple sclerosis and cancer: Navigating a dual diagnosis
Cassie Nesbitt, Anneke van der Walt, Helmut Butzkueven, et al.
Multiple Sclerosis Journal (2024)
Closed Access
Nanotechnology strategy for inhibition of PARP1 and IL-17A-associated with neurotoxicity in rats exposed to hospital wastewater
Hend A. Sabry, Elham H.A. Ali, Amany Ahmed Osman, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Open Access
Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells
N. A. Kolotyeva, Alexander A. Groshkov, Nataliya A. Rozanova, et al.
Biomolecules (2024) Vol. 14, Iss. 12, pp. 1556-1556
Open Access
Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy
Marianna Mekhaeil, Melissa J. Conroy, Kumlesh K. Dev
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1347-1368
Open Access | Times Cited: 1
Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation
Marianna Mekhaeil, Melissa J. Conroy, Kumlesh K. Dev
Journal of Neuroimmune Pharmacology (2023) Vol. 18, Iss. 4, pp. 592-609
Open Access | Times Cited: 1
Page 1

Scroll to top